Mp70-17 Global Disparities in Clinical Trials for Bladder Cancer Immune Checkpoint Inhibitors and Antibody-Drug Conjugates

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes III (MP70)1 May 2024MP70-17 GLOBAL DISPARITIES IN CLINICAL TRIALS FOR BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS AND ANTIBODY-DRUG CONJUGATES Juan C. Angulo-Lozano, Andres Noyola-Perez, Gabriel Cojuc-Konigsberg, Hector A. Vaquera, Claudia Mendoza, Luisa F. Sanchez, Jimena Alcocer, Pavel S. Pichardo-Rojas, Parwiz Abrahimi, Lina Posada Calderon, LaMont J. Barlow, and Douglas Scherr Juan C. Angulo-LozanoJuan C. Angulo-Lozano , Andres Noyola-PerezAndres Noyola-Perez , Gabriel Cojuc-KonigsbergGabriel Cojuc-Konigsberg , Hector A. VaqueraHector A. Vaquera , Claudia MendozaClaudia Mendoza , Luisa F. SanchezLuisa F. Sanchez , Jimena AlcocerJimena Alcocer , Pavel S. Pichardo-RojasPavel S. Pichardo-Rojas , Parwiz AbrahimiParwiz Abrahimi , Lina Posada CalderonLina Posada Calderon , LaMont J. BarlowLaMont J. Barlow , and Douglas ScherrDouglas Scherr View All Author Informationhttps://doi.org/10.1097/01.JU.0001008796.84999.75.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Immune checkpoint inhibitors (ICI) and antibody-drug conjugates (ADC) have shown unprecedented results in clinical trials for bladder cancer (BCa). Nonetheless, the affordability and accessibility of these drug classes in low- and middle-income countries (LMICs) is still uncertain. This study aimed to explore the global distribution of ongoing clinical trials for ICIs and ADCs. METHODS: We searched the NCT and WHO International Clinical Trials Registry Portal registries for trials on ICIs and ADCs for bladder cancer. Two reviewers, in a duplicated and blinded fashion, manually searched and extracted data from each registry searching ICIs and ADCs for BCa. The countries were classified according to the 2023 World Bank Ranking into High-income countries (HICs) and LMICs. RESULTS: 197 clinical trials were included from 60 participating countries, revealing disparities across income classifications. 38 (63.3%) were HICs, while 22 (36.7%) were LMICs (Figure 1). Comparing participation, from the 1317 country mentions in the 197 trials, HICs appeared 4.15 times more frequently than LMICs (80.6% Vs. 19.4%). There were no participating LMICs from Phase I RCTs. People living in HIC had 23.07 times more clinical trials per capita compared to those from LMIC (9.02-7 vs 3.9-8). There was a statistically significant difference in the distribution of HICs and LMICs between the 5 ICIs (p<0.001) and 3 ADCs (p=0.042) (Table 1). CONCLUSIONS: Disparities exist in the participation of countries according to their income, with HICs comprising most participants. While 84.7% the global population live in LMICs, conducting clinical trials in these countries can provide valuable insights into the effectiveness and safety of interventions in populations with different genetic, environmental, and socio-economic backgrounds. This not only ensures the generalizability of trial results but also ensures that healthcare solutions adjust to meet the needs of diverse populations. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1135 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Juan C. Angulo-Lozano More articles by this author Andres Noyola-Perez More articles by this author Gabriel Cojuc-Konigsberg More articles by this author Hector A. Vaquera More articles by this author Claudia Mendoza More articles by this author Luisa F. Sanchez More articles by this author Jimena Alcocer More articles by this author Pavel S. Pichardo-Rojas More articles by this author Parwiz Abrahimi More articles by this author Lina Posada Calderon More articles by this author LaMont J. Barlow More articles by this author Douglas Scherr More articles by this author Expand All Advertisement PDF downloadLoading ...